Acadian Asset Management LLC Has $29.10 Million Position in Alkermes plc $ALKS

Key Takeaways:

• Acadian Asset Management LLC’s position in Alkermes plc is valued at $29.10 million
• The holding represents a 2,422% increase in the first quarter
• Acadian purchased an additional 846,861 shares during the period
• The investor now holds 881,827 shares in Alkermes
• These figures come from the company’s most recent SEC filing

A Dramatic Increase

Acadian Asset Management LLC has made a noteworthy leap in its investment portfolio by significantly boosting its stake in Alkermes plc. According to a recent disclosure filed with the Securities and Exchange Commission (SEC), the firm’s position in the biotech company climbed to $29.10 million in the first quarter, underscoring Acadian’s growing interest in the NASDAQ-listed stock.

How the Numbers Stack Up

In concrete terms, Acadian’s move translated into a 2,422.0% surge in its holding in Alkermes. The institutional investor purchased an additional 846,861 shares, bringing its total to 881,827 shares. Below is a brief summary of the increase:

This dramatic jump highlights the scale of Acadian’s commitment. While the exact motivations behind the move are not detailed in the filing, the sheer size of the transaction stands out in the company’s portfolio changes.

Public Disclosure and Timing

All the relevant numbers regarding this investment change were made available through an SEC filing. The timing aligns with Acadian Asset Management’s first-quarter updates, offering investors and market observers insight into the firm’s shifting allocation strategies. Such filings often provide transparency into major institutional moves, revealing meaningful positions in corporate stocks.

Significance for Alkermes

Alkermes plc, a pharmaceutical company listed under the ticker ALKS on NASDAQ, garnered heightened attention following this substantial transaction. While the filing does not elaborate on Acadian’s outlook for Alkermes, the size of the stake alone indicates a pronounced level of confidence.

As of the first quarter, Acadian’s role as a notable institutional investor in Alkermes has grown profoundly. Its $29.10 million position showcases the firm’s strategic emphasis on the biotech sector, even if no further details on the rationale are provided.

Looking Ahead

With these disclosed figures, analysts and shareholders may watch for future moves by Acadian, or for any public statements regarding its perspective on Alkermes’ performance. For now, the available data underscores that Acadian made a decisive, substantial, and well-documented bet on Alkermes plc during the first quarter.